000403 派林生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.0445.2379.7098.5638.901
总资产报酬率 ROA (%)0.8764.4818.3387.3697.792
投入资产回报率 ROIC (%)0.9244.7828.9747.9998.489

边际利润分析
销售毛利率 (%)32.91741.53449.13251.48152.127
营业利润率 (%)12.44820.02633.16129.85327.583
息税前利润/营业总收入 (%)10.47817.63430.27127.07725.157
净利润/营业总收入 (%)10.24015.93628.06526.25824.434

收益指标分析
经营活动净收益/利润总额(%)96.958122.56198.379100.16398.707
价值变动净收益/利润总额(%)3.3962.6482.828-1.6811.206
营业外收支净额/利润总额(%)-4.468-5.379-3.229-1.029-0.460

偿债能力分析
流动比率 (X)3.0433.2973.7403.7153.176
速动比率 (X)1.5631.9122.4512.7292.526
资产负债率 (%)17.72714.63214.37114.00414.046
带息债务/全部投入资本 (%)12.9178.6447.1905.9874.511
股东权益/带息债务 (%)668.2041,048.7891,279.6641,551.4232,083.639
股东权益/负债合计 (%)464.462583.931596.391614.644612.517
利息保障倍数 (X)-7.287-12.868-16.344-10.952-10.939

营运能力分析
应收账款周转天数 (天)182.644106.71782.369109.718102.622
存货周转天数 (天)560.512327.066285.599244.231213.018